MedTrace Logo

The Role of 18F-FDG-PET/CT Scan in Lung Cancer Patients

NCT04395651 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2020-05-20

No results posted yet for this study

Summary

Describe strengths and limitations of FDG PET/CT for staging. Evaluate the utility of PET/CT in assessment of therapy response and restaging

Conditions

Interventions

DEVICE

PET/CT

It is a prospective clinical study that will include patients known to have lung cancer and referred to nuclear medicine unit to perform 18F-FDG PET/CT for staging and therapy planning as well as patients referred for assessment of response of therapy and restaging.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Taha Zaky Mahran, Prof.Dr. · Assiut University

  • Ahmad Zaher, Prof .Dr. · National Cancer Institute (NCI)

  • Nesreen Mekkawy, Dr. · Assiut University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-31
Primary Completion
2021-05-31
Completion
2021-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04395651 on ClinicalTrials.gov